comparemela.com
  1. Home
  2. Live Updates
  3. Greg Keenan - Breaking News

Latest Breaking News On - Greg keenan - Page 1 : comparemela.com

Long-Term Data, Renal Function Monitoring Update Added to Lupkynis Labeling

Long-Term Data, Renal Function Monitoring Update Added to Lupkynis Labeling
renalandurologynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from renalandurologynews.com Daily Mail and Mail on Sunday newspapers.

Greg keenanChief medical officer

Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation s Spring Clinical Meeting 2024

Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation s Spring Clinical Meeting 2024
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesErnie leeLily cipollaLisa kennedyMatt trumanRonald flautoMichelle zubryckiErnie yapStephen myersLucys hodgeMaria dalleraAnca askanaseVanessa birardiGreg keenanNeil solomonsRon flauto

Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024

Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
eagletribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eagletribune.com Daily Mail and Mail on Sunday newspapers.

United statesGabriel contrerasErnie yapMatt trumanNeil solomonsAndrea christopherKenneth kalunianMatthewg bakerGreg keenanMaria dalleraAnca askanaseLucys hodgeAurinia pharmaceuticals incEuropean commissionDrug administrationClinical program

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Q1 2024 Earnings Call Transcript

Aurinia Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.07464, expectations were $-0.17.

United statesFarzin haqueGreg keenanStacy kuAndrea christopherJoe millerPeter greenleafMaury raycroftInvestor relations for aurinia pharmaceuticalsExchange commissionAurinia pharmaceuticals first quarterHead of corporate communicationsAurinia pharmaceuticals incAurinia pharmaceuticalsCall transcript mayCorporate communications

Long-Term Data, Renal Function Monitoring Update Added to Lupkynis Labeling

The updated label now includes 3-year data from AURORA 2, a double-blind, placebo-controlled extension study.

Greg keenanChief medical officer

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.